Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aclasta zoledronic acid regulatory update

After an initial review of spontaneous post-marketing reports of atrial fibrillation (AF) in patents taking oral and IV bisphosphonates, FDA decided against recommending any changes

Read the full 250 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE